company background image
S49 logo

Supernus Pharmaceuticals DB:S49 Stock Report

Last Price

€29.80

Market Cap

€1.7b

7D

-7.5%

1Y

-11.3%

Updated

27 Mar, 2024

Data

Company Financials +

Supernus Pharmaceuticals, Inc.

DB:S49 Stock Report

Market Cap: €1.7b

S49 Stock Overview

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States.

S49 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Supernus Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Supernus Pharmaceuticals
Historical stock prices
Current Share PriceUS$29.80
52 Week HighUS$35.00
52 Week LowUS$21.40
Beta0.97
1 Month Change12.03%
3 Month Change12.03%
1 Year Change-11.31%
3 Year Change34.23%
5 Year Change-8.65%
Change since IPO623.83%

Recent News & Updates

Recent updates

Shareholder Returns

S49DE PharmaceuticalsDE Market
7D-7.5%4.0%2.5%
1Y-11.3%-24.6%7.0%

Return vs Industry: S49 exceeded the German Pharmaceuticals industry which returned -25.9% over the past year.

Return vs Market: S49 underperformed the German Market which returned 7.3% over the past year.

Price Volatility

Is S49's price volatile compared to industry and market?
S49 volatility
S49 Average Weekly Movement5.3%
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: S49 has not had significant price volatility in the past 3 months.

Volatility Over Time: S49's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2005652Jack Khattarhttps://www.supernus.com

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company’s commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson’s Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients.

Supernus Pharmaceuticals, Inc. Fundamentals Summary

How do Supernus Pharmaceuticals's earnings and revenue compare to its market cap?
S49 fundamental statistics
Market cap€1.71b
Earnings (TTM)€1.22m
Revenue (TTM)€561.17m

1,403x

P/E Ratio

3.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
S49 income statement (TTM)
RevenueUS$607.52m
Cost of RevenueUS$83.78m
Gross ProfitUS$523.74m
Other ExpensesUS$522.43m
EarningsUS$1.32m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.024
Gross Margin86.21%
Net Profit Margin0.22%
Debt/Equity Ratio0%

How did S49 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.